Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
Jesse S. Veisblatt, MD
Advertisement
Veisblatt is a postgraduate year 2 internal medicine resident at Temple University Hospital in Philadelphia, Pennsylvania. He plans to pursue a fellowship and career in infectious diseases.
Articles by Jesse S. Veisblatt, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Phase 3 Trial Confirms Superior Efficacy of Oral Pritelivir for Refractory HSV in Immunocompromised Patients
2
Invivyd Announces FDA Clearance of IND Application for VYD2311 and Advancement of REVOLUTION Clinical Program
3
UCF Team Advances Low-Cost Multiplex RNA Test for HIV, HBV, and HCV
4
